This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca PLC (AZN): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
AstraZeneca (AZN) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab
by Zacks Equity Research
Astrazeneca PLC (AZN) and its partner LEO Pharma received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain
by Zacks Equity Research
On May 19, we issued an updated research report on Boulder, CO based Clovis Oncology, Inc. (CLVS).
Endocyte (ECYT) Focused on Two Lead Pipeline Candidates
by Zacks Equity Research
We issued an updated report on Endocyte, Inc. (ECYT) on May 17.
AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study
by Zacks Equity Research
AstraZeneca PLC (AZN) recently announced positive data from a phase III PACIFIC study evaluating its oncology candidate, Imfinzi (durvalumab).
AstraZeneca (AZN) Shows Strength: Stock Moves 9.2% Higher
by Zacks Equity Research
AstraZeneca PLC (AZN) shares rose above 9% in the last trading session.
What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?
by Zacks Equity Research
Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.
Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study
by Arpita Dutt
While companies like Mylan (MYL), Allergan and Teva reported Q1 results this week, several companies provided updates on their cancer drugs.
Nektar Therapeutics (NKTR) Loss Wider Than Expected in Q1
by Zacks Equity Research
Nektar Therapeutics (NKTR) reported first-quarter 2017 loss of 42 cents per share, wider than the Zacks Consensus Estimate of a loss of 40 cents.
Ironwood (IRWD) Q1 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) reported first-quarter 2017 adjusted loss of 33 cents per share, significantly wider than both the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 8 cents.
Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit
by Arpita Dutt
Major pharma companies like Pfizer (PFE) and Merck reported Q1 results last week.
Company News for May 03, 2017
by Zacks Equity Research
Companies in the News are: COP,CVS,AZN,HLT
AstraZeneca (AZN) Q1 Earnings Beat, Revenues Meet Estimates
by Zacks Equity Research
AstraZeneca PLC (AZN) reported first-quarter 2017 core earnings of 99 cents per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 38 cents.
AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies
by Zacks Equity Research
AbbVie Inc. announced disappointing top-line results from two phase III studies evaluating veliparib in combination with chemotherapy for treatment of patients with squamous non-small cell lung cancer and triple negative breast cancer.
IntelliPharmaCeutics (IPCI) Q1 Loss Narrower Than Expected
by Zacks Equity Research
IntelliPharmaCeutics International Inc. (IPCI) reported loss of 7 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of a loss of 8 cents and the year-ago loss of 9 cents per share.
Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops
by Arpita Dutt
Key highlights this week include a complete response letter (CRL) for Merck (MRK) and some positive data from Roche.
5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now
by Zacks Equity Research
Paris, France based Sanofi (SNY) is a global healthcare company possessing a diversified product portfolio.
Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549
by Zacks Equity Research
We issued an updated report on Infinity Pharmaceuticals, Inc. (INFI) on Apr 7.
Dow 30 Stock Roundup: Boeing Bags Air Force Orders, DuPont to Sell Part of Crop Protection Biz
by Swarup Gupta
The Dow experienced a relatively quiet week as investors eagerly awaited the outcome of the Trump Xi meeting.
AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval
by Zacks Equity Research
AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received full approval from the FDA.
Pfizer Gets Regular Approval for Breast Cancer Drug Ibrance
by Zacks Equity Research
Pfizer, Inc. (PFE) announced that its supplemental new drug application (sNDA) to convert accelerated approval for Ibrance to regular approval has been approved by the FDA.
Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?
by Arpita Dutt
Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.
AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA
by Zacks Equity Research
AstraZeneca plc (AZN) announced that the FDA has accepted the new drug application (NDA) for Lynparza (300mg twice daily) for the maintenance treatment of patients suffering from platinum sensitive relapsed ovarian cancer with the germline BRCA mutation
Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula
by Zacks Equity Research
TESARO, Inc. (TSRO) recently announced that the FDA has approved its oral, once-daily poly(ADP-ribose) polymerase (PARP) inhibitor Zejula for ovarian cancer in women.
AstraZeneca's Lung Cancer Drug Tagrisso Approved in China
by Zacks Equity Research
AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received approval in China.